Search research articles
Contact Us
Filters
Showing results (1-10 of 53) with videos related to
Page
of 6
Sort By:
Cancer Cell
|
June 28, 2002
(Re-)Engineering tumor cell-selective replicating adenoviruses: a step in the right direction toward systemic therapy for metastatic disease
Thomas W Dubensky
Seminars in Immunology
|
May 22, 2010
Adjuvants for cancer vaccines
Thomas W Dubensky, Steven G Reed
Methods in Molecular Medicine
|
January 16, 2003
Generation of retroviral packaging and producer cell lines for large-scale vector production with improved safety and titer
Thomas W Dubensky, Sybille L Sauter
Expert Review of Vaccines
|
September 5, 2008
Promises and challenges for the development of Listeria monocytogenes-based immunotherapies
Dirk G Brockstedt, Thomas W Dubensky
Drug Discovery Today
|
July 12, 2002
Virus-based vectors for human vaccine applications
John M Polo, Thomas W Dubensky
Methods in Molecular Medicine
|
January 16, 2003
A highly efficient gene delivery system derived from feline immunodeficiency virus (FIV)
Sybille L Sauter, Mehdi Gasmi, Thomas W Dubensky
Therapeutic Advances in Vaccines
|
April 24, 2014
Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants
Thomas W Dubensky, David B Kanne, Meredith L Leong
Cancer Cell
|
October 31, 2003
Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology?
Martin A Giedlin, David N Cook, Thomas W Dubensky
Current Opinion in Biotechnology
|
May 22, 2012
Killed but metabolically active vaccines
Thomas W Dubensky, Justin Skoble, Peter Lauer, et al.
The Journal of Clinical Investigation
|
July 2, 2016
The host STING pathway at the interface of cancer and immunity
Leticia Corrales, Sarah M McWhirter, Thomas W Dubensky, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 53) with videos related to
Sort By:
Page
of 6
Cancer Cell
|
June 28, 2002
(Re-)Engineering tumor cell-selective replicating adenoviruses: a step in the right direction toward systemic therapy for metastatic disease
Thomas W Dubensky
Seminars in Immunology
|
May 22, 2010
Adjuvants for cancer vaccines
Thomas W Dubensky, Steven G Reed
Methods in Molecular Medicine
|
January 16, 2003
Generation of retroviral packaging and producer cell lines for large-scale vector production with improved safety and titer
Thomas W Dubensky, Sybille L Sauter
Expert Review of Vaccines
|
September 5, 2008
Promises and challenges for the development of Listeria monocytogenes-based immunotherapies
Dirk G Brockstedt, Thomas W Dubensky
Drug Discovery Today
|
July 12, 2002
Virus-based vectors for human vaccine applications
John M Polo, Thomas W Dubensky
Methods in Molecular Medicine
|
January 16, 2003
A highly efficient gene delivery system derived from feline immunodeficiency virus (FIV)
Sybille L Sauter, Mehdi Gasmi, Thomas W Dubensky
Therapeutic Advances in Vaccines
|
April 24, 2014
Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants
Thomas W Dubensky, David B Kanne, Meredith L Leong
Cancer Cell
|
October 31, 2003
Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology?
Martin A Giedlin, David N Cook, Thomas W Dubensky
Current Opinion in Biotechnology
|
May 22, 2012
Killed but metabolically active vaccines
Thomas W Dubensky, Justin Skoble, Peter Lauer, et al.
The Journal of Clinical Investigation
|
July 2, 2016
The host STING pathway at the interface of cancer and immunity
Leticia Corrales, Sarah M McWhirter, Thomas W Dubensky, et al.
Page
of 6